On November 4, 2026 Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") reported that an abstract highlighting data from its lead drug candidate, Annamycin, has been accepted for presentation at the 2026 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, taking place December 12-15, 2026 in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, titled "A Pivotal Phase 2/3 Study of Naxtarubicin as Second Line Therapy in Patients with AML," presents results from the first prespecified interim analysis of the Company’s pivotal MB-108 Phase 2/3 trial evaluating Annamycin in combination with cytarabine (Ara-C) in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).

Among the first 45 randomized patients evaluated, complete remission rates were 43% and 36% in the two Annamycin treatment arms, respectively, compared to 12% in the placebo arm. Consistent with findings across Annamycin’s clinical development program to date, no signs, symptoms or echocardiographic findings suggestive of cardiotoxicity were observed through the data cutoff. All cardiac safety data will undergo independent expert and independent Data Monitoring Committee review at the second interim analysis. Following its review, the independent Data Monitoring Committee recommended that the study continue without amendment, with all three treatment arms maintained.

"We are encouraged by these initial findings from our pivotal Phase 2/3 trial, particularly the remission rates observed in the Annamycin treatment arms. The independent Data Monitoring Committee’s recommendation to continue the study without modification represents an important milestone for the program. We look forward to sharing these findings with the broader hematology community at ASH (Free ASH Whitepaper) as we continue advancing Annamycin’s development for patients facing this challenging disease," commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin.

The MIRACLE Trial (MB-108) is designed to confirm the efficacy and safety findings observed in the Company’s completed MB-106 Phase 1/2 trial and, if successful, could support a New Drug Application submission, consistent with the Company’s agreement with the U.S. Food and Drug Administration. As previously announced, the second interim analysis is expected in early 2027.

Presentation Details

Meeting: 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting
Abstract Title: A pivotal Phase 2/3 study of naxtarubicin as second line therapy in patients with AML
Presentation Type: Poster
Presenting Author: Oksana Karnabeda, MD, PhD, Arensia Exploratory Medicine, LLC
Location: Ernest N. Morial Convention Center – Hall F (Poster Hall), 900 Convention Center Blvd, New Orleans, LA 70130
The abstract will be available through the ASH (Free ASH Whitepaper) Annual Meeting website.

(Press release, Moleculin, NOV 4, 2026, View Source [SID1234674173])